NPs have also been tested to predict CLL prognosis by engineering AuNPs with an oligonucleotide targeting a specific sequence of the ZAP70 gene associated with the IGHV mutational status. This evidence concerns the gene ZAP70 and B-cell chronic lymphocytic leukemia.